Picture of Ion Beam Applications SA logo

IBAB — Ion Beam Applications SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Brief: IBA: Japanese Approval For Reimbursement Of Amyloid-PET Diagnostic Neuraceq In Alzheimer's Disease

Dec 13 (Reuters) - Ion Beam Applications SA  IBAB.BR :
    * IBA, CMI AND LIFE MOLECULAR IMAGING ANNOUNCE JAPANESE
APPROVAL
FOR THE REIMBURSEMENT OF AMYLOID-PET DIAGNOSTIC NEURACEQ® IN
ALZHEIMER'S DISEASE
    * JAPANESE MINISTRY OF HEALTH HAS APPROVED REIMBURSEMENT BY
GOVERNMENTAL HEALTH INSURANCE OF AMYLOID POSITRON EMISSION
TOMOGRAPHY (PET) DIAGNOSTIC NEURACEQ® (FLORBETABEN 18F)
    * NEURACEQ IS FIRST AMYLOID PET DIAGNOSTIC TOOL REIMBURSED
IN
JAPAN

Source text for Eikon:  ID:nGNEbNtGH3 
Further company coverage:  IBAB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Ion Beam Applications SA

See all news